GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (NAS:VKTX) » Definitions » Cash Flow from Investing

Viking Therapeutics (Viking Therapeutics) Cash Flow from Investing : $-641.08 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Viking Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $596.60 Mil on purchasing investments. It gained $136.81 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $0.00 Mil from other investing activities. In all, Viking Therapeutics spent $459.79 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Viking Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Viking Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Cash Flow from Investing Chart

Viking Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.46 41.57 37.96 54.75 -179.09

Viking Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.20 -204.48 -12.53 35.73 -459.79

Viking Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Viking Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Viking Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-641.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viking Therapeutics  (NAS:VKTX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Viking Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Viking Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Viking Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Viking Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Viking Therapeutics's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Viking Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Viking Therapeutics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Viking Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Viking Therapeutics's purchase of investment for the three months ended in Mar. 2024 was $-596.60 Mil. It means Viking Therapeutics spent {stock_data.stock.currency_symbol}}596.60 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Viking Therapeutics's sale of investment for the three months ended in Mar. 2024 was $136.81 Mil. It means Viking Therapeutics gained $136.81 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Viking Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Viking Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Viking Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Viking Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Viking Therapeutics's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Viking Therapeutics received $0.00 Mil from other investing activities.


Viking Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Viking Therapeutics (Viking Therapeutics) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Executives
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Greg Zante officer: Chief Financial Officer C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Lawson Macartney director C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Brian Lian director, officer: President & CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Marianna Mancini officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130
Matthew W Foehr director 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Hiroko Masamune officer: Chief Development Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Michael Morneau officer: Chief Financial Officer C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
J Matthew Singleton director 286 STANWICH ROAD, GREENWICH CT 06830
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Rochelle Hanley officer: Chief Medical Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037
Michael Dinerman officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037